| Bioactivity | KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research[1]. |
| Invitro | KWAR 23 (0-1 μM; 4 h) shows antitumor activity of human neutrophil and macrophage[1].KWAR 23 induces human macrophage-dependent phagocytosis in human tumor-derived cell lines[1]. Cell Viability Assay[1] Cell Line: |
| In Vivo | KWAR23 (intraperitoneal injection; 10 mg/kg; every other day; 21 d) exhibits effective antitumor activity in a human SIRPA knockin mouse model[1].KWAR23 enhances neutrophil and macrophage antitumor activity in SRG Mice[1]. Animal Model: |
| Name | KWAR 23 |
| CAS | 2243227-60-1 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ring NG, et al. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):E10578-E10585. |